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EDITORIAL
Bladder cancer is a common disease, and 
for T2-T4 stages, radical cystectomy is the first 
treatment option (1). An interesting Swedish study 
has evaluated the natural history of urothelial bla-
dder cancer. After 6 months of diagnosis, 38% of 
patients develop metastasis if untreated (2). Five-
-year Cancer-specific survival is as low as 14% in 
such scenery, and overall survival is only 5% (2). 
On the other hand, if treated these patients have a 
5-year CSS and OS of 60% and 48% respectively 
(2). Radical cystectomy is, therefore, the first op-
tion, as it is also stated by the EAU, NCCN, AUA / 
ASCO / ASTRO / SUO guidelines/consensus (3-5) is 
associated with a significant survival gain in com-
parison to observation (2), to multiple resections, 
chemotherapy or radiotherapy (6). In patients with 
stage II disease, cystectomy is associated with a 
three-fold increase in survival, increasing mean 
overall survival from 16 to 45 months (6). In a 
SEER study evaluating 328,560 patients, radi-
cal cystectomy and chemotherapy were the only 
factors associated with improvements in survival 
(7). Trimodal “bladder-sparing” approaches that 
combine maximal transurethral resection, chemo-
therapy, and radiotherapy or neoadjuvant chemo-
therapy with partial cystectomy are an option but 
only for a small percentage of patients (3).
 However, if we analyze data carefully, the 
guideline recommendations are rarely followed. 
In a SEER study that evaluated 6.737 patients in 
the USA with stage II disease (non-metastatic, 
muscle-invasive bladder cancer), only 8.3% un-
derwent radical cystectomy (8). The odds of an oc-
togenarian to undergo radical cystectomy in the 
USA is five-times lower than a young patient (8). 
Hispanic origin, Afro-American origin, and lower 
scholar level patients are also less treated properly 
when they have muscle-invasive bladder cancer 
(8). According to a very interesting study that eva-
luated 27,578 patients from the SEER, only 6% 
of patients with muscle-invasive bladder cancer 
(pT2-pT4) in the USA underwent radical cystec-
tomy between 2007 and 2013 (8). Less than 19% 
of patients with pT2 disease in the USA undergo 
radical cystectomy (9).
And why does this happen? The answer is 
because radical cystectomy is associated with high 
morbidity and mortality rates. When described in 
the late 1940s, radical cystectomy was associa-
ted with a perioperative mortality of 33% (10). 
In the 1970s perioperative mortality decreased to 
11% (and remained around 2.1% to 4.7% after the 
1980s) (11). Analyzing mortality after radical cys-
tectomy is a slippery slope, as demonstrated in Ta-
ble-1. Studies report distinctive data. In-hospital 
mortality is lower than 30-day mortality, which 
is two to three-fold lower than 90-day mortality. 
And these numbers vary widely (1, 12, 13).
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In large volume academic referral centers 
in the USA, in-hospital mortality after 6,728 cys-
tectomies was as low as 0.54% (14). This results 
are impressive, and can be either effect of expe-
rience but also to a high selection bias. If we go to 
other less selected settings, things start to change. 
An Australian epidemiologic study has observed a 
2.2% rate after 803 surgeries (15). A British stu-
dy evaluated 15,292 patients and have observed 
a mortality rate of 2.7% after 30 days and of 7% 
after 90 months (12). In a large epidemiologic 
study evaluating SEER data, the mortality rate of 
47,028 patients who underwent radical cystec-
tomy in 1,162 centers was 3% after 30 days and 
8.2% after 90 days (1). In another large SEER stu-
dy with 7,076 patients, 90-day mortality ranged 
from 10.75% to 13.1% (16). In Spain  a national 
database study that has evaluated 7,999 patients 
found a 4.7% in-hospital mortality and 6.2% 90-
day mortality rate (17).
In developing countries, reality seems to 
be much tougher in the public scenario. We have 
recently published a study demonstrating a 7.38% 
in-hospital mortality rate, with a wide variation 
according to geographic regions, varying from 
6.2% in the south to 28.6% in certain regions of 
the North of Brazil (18). Data from the public he-
alth system (DATASUS) in the State of São Paulo, 
the most populated and wealthier state of Brazil, 
between 2008-2018 demonstrated amid 1,377 ra-
dical cystectomies reported, and 117 in-hospital 
deaths (8.5%). In the five largest academic institu-
tions in the city of São Paulo that treat exclusively 
patients from the public health system, in-hospital 
mortality varied from 6.0% to 15.9% (18). And it 
is important to state that these numbers represent 
in-hospital mortality. Probably 90-day mortality 
is even higher. 
Ureterostomy as a strategy to reduce mortality?
Even though the AUA / ASCO / ASTRO / 
SUO guidelines recommend as first-line treatment 
for MIBC not only radical cystectomy but also uri-
nary diversion using intestinal segments (ileal con-
duit, continent cutaneous diversion or orthotopic 
neobladder) as standard treatments (4), this is not 
what is currently done in more than 90% of pa-
tients with MIBC in the USA, where only a fraction 
of patients with MIBC undergo radical cystectomy. 
Data evaluating a series of patients undergoing ra-
dical cystectomy in developing countries are scarce 
in the literature, mainly because mortality rates are 
Table 1 - Mortality after radical cystectomy in distinctive settings. 
Author N IHM 30-day 90-day Setting
Barbieri, 2019, (14) 6,728 0.54% - - Large volume academic centers
Udovicich, 2017. (15) 803 2.2% - - Victoria state, Australia
Afshar, 2018, (12) 15,292 2.7% 7% English database
Afshar, 2018, (19) 1.5% 4% English database (after 
centralization program)
Waingankar, 2019, (1) 47,028 3.0% 8.2% SEER, USA
Dell’Oglio, 2019, (16) 7,076 - - 10.7% SEER, USA
Timoteo, 2019, (18) 5.097 7.38% - - DATASUS, Brasil
DATASUS, 2019 1,377 8.5% - - DATASUS, state of SP
DATASUS, 2019 161 8.1% - DATASUS, institution 1, São Paulo
DATASUS, 2019 84 6.0% - DATASUS, institution 2, São Paulo
DATASUS, 2019 71 11.3% - DATASUS, institution 3, São Paulo
DATASUS, 2019 53 15.9% - DATASUS, institution 4, São Paulo
DATASUS, 2019 81 14.8% - - DATASUS, suburban institutions 
of São Paulo
IHM = in-hospital mortality
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unacceptable in most public large volume centers. 
Some key points that have been adopted by Eu-
ropean centers might urgently be adopted in the 
developing world (3). They include centralization 
of treatment and surgeries to referral centers (19, 
20), proper patient preparation and adequate choi-
ce of diversion for each patient (12, 21). In high 
risk patients, cutaneous ureterostomy might be also 
considered as a good alternative (3, 22). Several au-
thors have demonstrated a significant reduction in 
complications and mortality with cutaneous urete-
rostomy after radical cystectomy mainly in patients 
with high risk for complications; it reduces the du-
ration of the surgery and all the complications rela-
ted to bowel manipulation, thus decreasing the risk 
of mortality in patients with comorbidities (22-25).
Some key-points are that not every patient 
with MIBC is a candidate for radical cystectomy, 
but also not every patient suitable for radical cys-
tectomy is a candidate for urinary diversion with 
intestinal segments. Urinary diversion using in-
testinal segments is responsible for a large num-
ber of these deaths (23). Even though this insight 
has been widely published before (22-25), mor-
tality rates at many Centers are still high. If in 
one hand we discuss robotic use (21, 26-28) that is 
been used in the vast majority of patients treated 
with muscle-invasive bladder cancer, we have to 
talk about this problem in our journals, meetings, 
boards, and discussions and bring better solutions 
to be sure that we are first of all not harming our 
patients. We have to properly perform a correct 
pre/intra/postop management of the patients and 
therapeutic decisions might be in accordance to 
comorbidities and life expectancy.
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